Member Info for andyrp

The sell off on the back of this refusal is bigger than any previous in my experience of UKOG. I suspect many holders are done with this now. It’s sad because once upon a time I really believed in the UKOG dream but simply couldn’t take any more damage to my portfolio so cut my losses.

They need to have a very clear 2 forms of response as it is never clear to some of the committee whether they need to say accept the motion to refuse, refuse the motion to refuse or refuse the planning application.

Last time around they didn’t know whether they were objecting to pass it or accepting to reject it!

It was Thursday when he posted saying “tomorrow”!

No longer invested but watching with interest. In all other SCC planning meetings I have watched this guy knew his stuff. He should do as he as an ex. council Planning department leader / head. He’s very clear that objection has to have merit on planning grounds and not simply because somebody doesn’t like the idea.

Refer to Points 37 onwards for testing plans. Plenty to go at yet I think.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/937529/COVID-19_Winter_Plan.pdf

Savvy6 I’ve often thought that if MM need shares to fill an order why don’t they put the price up; like a reverse tree shake. Shares seems to be the only thing where the price falls when there is demand; in every other traded item or service the price goes up as demand increases. To me that is what makes it feel a little corrupt because they are giving huge discounts to their city chums at the expense of PIs. It is not a level playing field!

Steve Sanderson and Michael de Guzman in the same room together? Could they be the same person? The modus operandi has many parallels!

IMO.

Loxley will kick start another round of dilution! That’s the only guarantee here.

Do you think the UK Government is building new testing mega labs because the vaccine will solve the pandemic on its own? The virus is going to be here for a long time, the long term immunity of the vaccine is unknown, the virus is mutating (NCYT are very good at reacting and developing new tests), testing will go hand in hand with the vaccination program - see it as a massive study to assess the effectiveness of the vaccines, the vaccination program will take over 12 months to reach the target patient cohorts, public confidence in the vaccine safety is relatively low so might big be insufficient take up meaning virus can still spread quickly.

The vaccine is not a threat to those diagnostics companies that have products on the market but only to those who have not yet launched as they might be too late now.

Don't forget that a vaccination program needs certain (high) proportion of the population to be vaccinated and there is a lot of concern that the vaccine has been rushed through and a lot of people will be refusing it.

Copied from the SNG board! I was tempted to do the same.

That RNS is just a load of caveats to pre-empt poor flow rates and volumes in the next OGA report. If there was anything positive SS would have said it.

Zwart you may well be right - this is a product that is going to be in demand globally. We have seen it with Covid testing companies where they can literally sell every single unit they manufacturer because the demand is so great. When you are talking about improved patient outcomes then it becomes blindingly obvious where this is going.

In the race to contain CV19 and reduce impact on healthcare systems globally I think we are going to see governments throwing the proverbial kitchen sink at solutions. We should be on standby for emergency approvals of a multitude of therapeutics that have shown positive Phase II clinical trial outcomes (e.g. patient safety has been demonstrated and evidence of therapeutic benefit confirmed). Globally we cannot afford to wait for Phase III trials to conclude so I expect to see some commercialisation of SNG001 much sooner than we might otherwise have expected.

Another acquisition target for NCYT. Imspex have the technology but have neither the finances or market position to make this a reality. We already know the speed at which NCYT can bring new products to market so this could be a good match.

My plan was to take advantage a colleague had the audacity to walk on to my office to talk about work stuff! Next time I looked it was rocketing but still a good enough SP and didn’t stop me getting back on board though!

I sold my latest holding at £9.93 whilst waiting in the queue at the fish and chip ship the other day when the attack on the SP got going - this of course makes me a "panicker" but one who safeguarded a nice profit and for the first time in my dreadful investment history I now find myself able to buy back more shares for less money. Without doubt I am waiting for the opportunity to buy back here as we all know the fundamentals are excellent but I needed to safeguard my profit after some very bitter experiences with other shares this last year.

I disagree, there was a talk and hope amongst SYME PIs about a deal between SYME and RR, not necessarily with any substance, but now that deal has effectively been ruled out there is an impact on the SYME share price.

I suspect todays dip is purely down to the latest RNS from Rolls Royce as some SYME investors were expecting a deal with RR to have been struck. RR is just one deal; look at what else is out there!!!!!